More importantly, PTEN status was consistent between matched CSPC and CRPC tumor biopsies in nearly 90% of cases [52], meaning that the loss of PTEN is an early event in prostate cancer tumorigenesis. The gene discussed is PTEN; the disease is neoplasm.